Clinical Trial Update: Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating lutetium Lu-177 dotatate (Lutathera) in combination with olaparib for inoperable gastroenteropancreatic neuroendocrine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Neoplasm
• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastroenteropancreatico Tumors, Neuroendocrine Tumors | Phase 1, Phase 2 | Status: RECRUITING